Effector Total Operating Expenses vs Gross Profit Analysis

EFTR Stock  USD 2.25  0.18  8.70%   
Effector Therapeutics financial indicator trend analysis is much more than just examining Effector Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Effector Therapeutics is a good investment. Please check the relationship between Effector Therapeutics Total Operating Expenses and its Gross Profit accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Effector Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
To learn how to invest in Effector Stock, please use our How to Invest in Effector Therapeutics guide.

Total Operating Expenses vs Gross Profit

Total Operating Expenses vs Gross Profit Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Effector Therapeutics Total Operating Expenses account and Gross Profit. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Effector Therapeutics' Total Operating Expenses and Gross Profit is -0.28. Overlapping area represents the amount of variation of Total Operating Expenses that can explain the historical movement of Gross Profit in the same time period over historical financial statements of Effector Therapeutics, assuming nothing else is changed. The correlation between historical values of Effector Therapeutics' Total Operating Expenses and Gross Profit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Operating Expenses of Effector Therapeutics are associated (or correlated) with its Gross Profit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Gross Profit has no effect on the direction of Total Operating Expenses i.e., Effector Therapeutics' Total Operating Expenses and Gross Profit go up and down completely randomly.

Correlation Coefficient

-0.28
Relationship DirectionNegative 
Relationship StrengthInsignificant

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Effector Therapeutics minus its cost of goods sold. It is profit before Effector Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.
Most indicators from Effector Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Effector Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Effector Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
To learn how to invest in Effector Stock, please use our How to Invest in Effector Therapeutics guide.At this time, Effector Therapeutics' Issuance Of Capital Stock is relatively stable compared to the past year. As of 05/01/2024, Sales General And Administrative To Revenue is likely to grow to 3.47, while Selling General Administrative is likely to drop slightly above 10.1 M.
 2021 2022 2023 2024 (projected)
Total Operating Expenses31.9M32.4M33.7M33.6M
Cost Of Revenue24K53K111K105.5K

Effector Therapeutics fundamental ratios Correlations

0.790.11-0.480.20.88-0.79-0.860.210.370.940.340.930.851.00.770.990.810.251.0-0.580.82-0.87-0.320.820.83
0.790.60.130.610.95-0.58-0.44-0.230.720.620.620.850.620.790.920.740.94-0.240.790.010.93-0.59-0.520.930.94
0.110.60.510.950.340.230.1-0.340.410.030.820.130.050.10.410.090.42-0.90.10.450.420.25-0.210.430.42
-0.480.130.510.34-0.040.290.8-0.630.47-0.680.15-0.2-0.44-0.480.12-0.560.09-0.54-0.480.990.070.43-0.190.070.06
0.20.610.950.340.330.280.0-0.170.280.120.950.130.20.180.330.190.36-0.90.190.290.370.24-0.130.370.37
0.880.950.34-0.040.33-0.81-0.58-0.210.740.730.360.960.650.880.960.840.970.080.88-0.170.96-0.81-0.590.960.96
-0.79-0.580.230.290.28-0.810.640.08-0.56-0.710.23-0.9-0.54-0.8-0.78-0.75-0.77-0.63-0.80.39-0.760.980.5-0.76-0.76
-0.86-0.440.10.80.0-0.580.64-0.440.0-0.97-0.14-0.68-0.72-0.86-0.48-0.91-0.51-0.37-0.870.87-0.530.750.08-0.53-0.54
0.21-0.23-0.34-0.63-0.17-0.210.08-0.44-0.80.270.080.00.590.21-0.290.24-0.210.220.21-0.58-0.15-0.050.83-0.17-0.14
0.370.720.410.470.280.74-0.560.0-0.80.20.130.590.010.370.790.310.75-0.080.370.360.7-0.46-0.890.710.69
0.940.620.03-0.680.120.73-0.71-0.970.270.20.240.790.740.940.630.970.650.30.94-0.770.67-0.81-0.270.660.67
0.340.620.820.150.950.360.23-0.140.080.130.240.210.430.320.290.340.36-0.790.320.110.370.140.010.360.37
0.930.850.13-0.20.130.96-0.9-0.680.00.590.790.210.770.930.920.880.940.280.93-0.310.94-0.91-0.430.940.94
0.850.620.05-0.440.20.65-0.54-0.720.590.010.740.430.770.850.530.840.620.160.85-0.50.65-0.650.160.640.66
1.00.790.1-0.480.180.88-0.8-0.860.210.370.940.320.930.850.770.990.810.261.0-0.580.82-0.88-0.320.820.83
0.770.920.410.120.330.96-0.78-0.48-0.290.790.630.290.920.530.770.710.990.020.77-0.010.99-0.75-0.570.990.99
0.990.740.09-0.560.190.84-0.75-0.910.240.310.970.340.880.840.990.710.760.250.99-0.650.76-0.85-0.30.760.77
0.810.940.420.090.360.97-0.77-0.51-0.210.750.650.360.940.620.810.990.760.00.81-0.041.0-0.75-0.511.01.0
0.25-0.24-0.9-0.54-0.90.08-0.63-0.370.22-0.080.3-0.790.280.160.260.020.250.00.26-0.540.0-0.63-0.060.00.0
1.00.790.1-0.480.190.88-0.8-0.870.210.370.940.320.930.851.00.770.990.810.26-0.580.82-0.88-0.320.810.82
-0.580.010.450.990.29-0.170.390.87-0.580.36-0.770.11-0.31-0.5-0.58-0.01-0.65-0.04-0.54-0.58-0.060.53-0.1-0.06-0.07
0.820.930.420.070.370.96-0.76-0.53-0.150.70.670.370.940.650.820.990.761.00.00.82-0.06-0.75-0.461.01.0
-0.87-0.590.250.430.24-0.810.980.75-0.05-0.46-0.810.14-0.91-0.65-0.88-0.75-0.85-0.75-0.63-0.880.53-0.750.43-0.75-0.75
-0.32-0.52-0.21-0.19-0.13-0.590.50.080.83-0.89-0.270.01-0.430.16-0.32-0.57-0.3-0.51-0.06-0.32-0.1-0.460.43-0.47-0.44
0.820.930.430.070.370.96-0.76-0.53-0.170.710.660.360.940.640.820.990.761.00.00.81-0.061.0-0.75-0.471.0
0.830.940.420.060.370.96-0.76-0.54-0.140.690.670.370.940.660.830.990.771.00.00.82-0.071.0-0.75-0.441.0
Click cells to compare fundamentals

Effector Therapeutics Account Relationship Matchups

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Effector Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Effector Therapeutics' short interest history, or implied volatility extrapolated from Effector Therapeutics options trading.

Pair Trading with Effector Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Effector Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Effector Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Effector Stock

  0.66DVAX Dynavax Technologies Financial Report 7th of May 2024 PairCorr
  0.69EGRX Eagle PharmaceuticalsPairCorr
  0.82ELAN Elanco Animal Health Financial Report 14th of May 2024 PairCorr

Moving against Effector Stock

  0.75ACB Aurora Cannabis TrendingPairCorr
  0.6CGC Canopy Growth Corp TrendingPairCorr
  0.46HCM HUTCHMED DRCPairCorr
The ability to find closely correlated positions to Effector Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Effector Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Effector Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Effector Therapeutics to buy it.
The correlation of Effector Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Effector Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Effector Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Effector Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Effector Therapeutics is a strong investment it is important to analyze Effector Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Effector Therapeutics' future performance. For an informed investment choice regarding Effector Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Effector Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
To learn how to invest in Effector Stock, please use our How to Invest in Effector Therapeutics guide.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Effector Stock analysis

When running Effector Therapeutics' price analysis, check to measure Effector Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Effector Therapeutics is operating at the current time. Most of Effector Therapeutics' value examination focuses on studying past and present price action to predict the probability of Effector Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Effector Therapeutics' price. Additionally, you may evaluate how the addition of Effector Therapeutics to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Money Managers
Screen money managers from public funds and ETFs managed around the world
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Transaction History
View history of all your transactions and understand their impact on performance
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Is Effector Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Effector Therapeutics. If investors know Effector will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Effector Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(16.37)
Revenue Per Share
0.349
Quarterly Revenue Growth
1.17
Return On Assets
(0.85)
Return On Equity
(9.47)
The market value of Effector Therapeutics is measured differently than its book value, which is the value of Effector that is recorded on the company's balance sheet. Investors also form their own opinion of Effector Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Effector Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Effector Therapeutics' market value can be influenced by many factors that don't directly affect Effector Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Effector Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Effector Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Effector Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.